A study from Milan Italy look at the controversy, does the testosterone level achieved with androgen-deprivation therapy (ADT) increase the survival in men with metastatic prostate cancer? ADT comes with significant morbidity issues, so is there an adequate benefit from ADT (does it provide survival benefits) to balance out the negative side effects? This is the million dollar question.

The researchers, Perachino M, Cavalli V, Bravi F., retrospectively reviewed the records of 129 men with a histological diagnosis of metastatic bony-only prostate cancer and previously untreated with ADT. They then treated the men